AR024472A1 - Inhibidores de la integrina alfav beta6. - Google Patents

Inhibidores de la integrina alfav beta6.

Info

Publication number
AR024472A1
AR024472A1 ARP000103177A ARP000103177A AR024472A1 AR 024472 A1 AR024472 A1 AR 024472A1 AR P000103177 A ARP000103177 A AR P000103177A AR P000103177 A ARP000103177 A AR P000103177A AR 024472 A1 AR024472 A1 AR 024472A1
Authority
AR
Argentina
Prior art keywords
ala
asp
arg
phe
gly
Prior art date
Application number
ARP000103177A
Other languages
English (en)
Spanish (es)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR024472A1 publication Critical patent/AR024472A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP000103177A 1999-06-26 2000-06-23 Inhibidores de la integrina alfav beta6. AR024472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929410A DE19929410A1 (de) 1999-06-26 1999-06-26 Inhibitoren des Integrins avß6

Publications (1)

Publication Number Publication Date
AR024472A1 true AR024472A1 (es) 2002-10-02

Family

ID=7912712

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103177A AR024472A1 (es) 1999-06-26 2000-06-23 Inhibidores de la integrina alfav beta6.

Country Status (17)

Country Link
EP (1) EP1189930A1 (de)
JP (1) JP2003503422A (de)
KR (1) KR20020015704A (de)
CN (1) CN1358195A (de)
AR (1) AR024472A1 (de)
AU (1) AU771099B2 (de)
BR (1) BR0011954A (de)
CA (1) CA2377224A1 (de)
CZ (1) CZ20014484A3 (de)
DE (1) DE19929410A1 (de)
HU (1) HUP0201729A3 (de)
MX (1) MXPA01013247A (de)
NO (1) NO20016341L (de)
PL (1) PL352374A1 (de)
SK (1) SK18722001A3 (de)
WO (1) WO2001000660A1 (de)
ZA (1) ZA200200673B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE502004007051D1 (de) * 2003-02-06 2008-06-19 Merck Patent Gmbh Peptidische sulfonamide
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
EP2064244B1 (de) 2006-08-03 2019-06-05 MedImmune Limited GEGEN alphaVbeta6 GERICHTETE ANTIKÖRPER UND IHRE VERWENDUNG
SI3535397T1 (sl) 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
WO2019089765A1 (en) 2017-11-01 2019-05-09 Arrowhead Pharmcaceuticals, Inc. Integrin ligands and uses thereof
JP2024516096A (ja) 2021-04-08 2024-04-12 アローヘッド ファーマシューティカルズ インコーポレイテッド 終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2029392A (en) * 1991-05-14 1992-12-30 Board Of Regents Of The University Of Oklahoma, The Peptide inhibitors of inflammation
ATE511850T1 (de) * 1997-08-08 2011-06-15 Univ California Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin
CZ20012212A3 (cs) * 1998-12-19 2001-09-12 Merck Patent Gmbh Peptidická sloučenina, její použití a farmaceutický prostředek, který ji obsahuje

Also Published As

Publication number Publication date
AU6263000A (en) 2001-01-31
JP2003503422A (ja) 2003-01-28
ZA200200673B (en) 2003-04-24
CZ20014484A3 (cs) 2002-04-17
EP1189930A1 (de) 2002-03-27
NO20016341L (no) 2002-02-25
KR20020015704A (ko) 2002-02-28
DE19929410A1 (de) 2000-12-28
CN1358195A (zh) 2002-07-10
PL352374A1 (en) 2003-08-25
HUP0201729A3 (en) 2005-01-28
HUP0201729A2 (en) 2002-08-28
CA2377224A1 (en) 2001-01-04
MXPA01013247A (es) 2002-07-02
SK18722001A3 (sk) 2002-05-09
BR0011954A (pt) 2002-05-07
AU771099B2 (en) 2004-03-11
WO2001000660A1 (de) 2001-01-04
NO20016341D0 (no) 2001-12-21

Similar Documents

Publication Publication Date Title
AR039231A1 (es) Agentes de union ox40r novedosos
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
DK1941867T3 (da) Polypeptid med modificeret Kunitz domæne
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
CY1110927T1 (el) Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων
FR2842209B1 (fr) Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
ATE171712T1 (de) Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
DE69009476D1 (de) Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.
AR024472A1 (es) Inhibidores de la integrina alfav beta6.
ATE443076T1 (de) Von protease typ ii spaltbares peptid
ATE478089T1 (de) Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen
ES2058873T3 (es) Antagonistas peptidicos sinteticos de neuroquinina a, sus sales y procedimientos de preparacion respectivos.
AR020101A1 (es) Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
NO20034146D0 (no) Syntetiske peptider og fremgangsmåte for forebyggende og terapeutisk anvendelse i kreftinvasjon og metastase
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
NO20052525L (no) Spleisevariant av humant hypofyseveksthormon
ES2119746T3 (es) Nuevo peptido fisiologicamente activo y agente regulador del metabolismo del calcio que comprende dicho peptido como ingrediente activo.
ATE438660T1 (de) Neue menschliche g-protein gekoppelten rezeptoren und dafür kodierende polynucleotide
DE60129228D1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
TH56074A3 (th) ตัวยับยั้ง อัลฟาv เบตา6 อินทีกริน
LT2004079A (en) Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis
Yusuf et al. 1-Tetralinyl as Carboxamide-Protecting Group for Asparagine and Application to N-α-t-Butyloxycarbonyl (Boc) Solid-phase Peptide Synthesis of Oxytocin

Legal Events

Date Code Title Description
FA Abandonment or withdrawal